Mereo fights revolt by largest shareholder Rubric

UK biotech Mereo BioPharma is attempting to face down a revolt by Rubric Capital Management – its largest shareholder holding around 14% of the company – which is agitating for changes to i

Mereo raises $70m as TIGIT cancer drug progresses in clinic

Mereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. 

Mereo’s brittle bone drug likely to shrug off phase 2b fail,...

After delayed IPO, Mereo gets US listing via OncoMed merger

UK biotech Mereo BioPharma is merging with Californian biotech OncoMed in an all-stock deal that swells its pipeline and gives it a potential licensing deal with Celgene.